Patent Ductus Arteriosus (PDA)

0
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Merit Medical
Merit MedicalSOUTH JORDAN, UT
1 program
Bloom Micro Occluder SystemN/A1 trial
Active Trials
NCT06587282Recruiting55Est. Mar 2029
Abbott
AbbottABBOTT PARK, IL
1 program
Device closure with AMPLATZER Duct OccluderN/A1 trial
Active Trials
NCT00583596Completed436Est. Feb 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Merit MedicalBloom Micro Occluder System
AbbottDevice closure with AMPLATZER Duct Occluder

Clinical Trials (2)

Total enrollment: 491 patients across 2 trials

NCT06587282Merit MedicalBloom Micro Occluder System

PREEMIE: Study for Treatment of PDA in Premature Infants

Start: Mar 2025Est. completion: Mar 202955 patients
N/ARecruiting
NCT00583596AbbottDevice closure with AMPLATZER Duct Occluder

Closure Of Patent Ductus Arteriosus With the AMPLATZER Duct Occluder the AMPLATZER® Duct Occluder

Start: Oct 1999Est. completion: Feb 2009436 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 491 patients
2 companies competing in this space